Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice (Q39345406)
Jump to navigation
Jump to search
scientific article published on 18 May 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice |
scientific article published on 18 May 2012 |
Statements
1 reference
Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice (English)
1 reference
Kinya Inoue
1 reference
Takuji Torimura
1 reference
Toru Nakamura
1 reference
Hideki Iwamoto
1 reference
Hiroshi Masuda
1 reference
Mitsuhiko Abe
1 reference
Osamu Hashimoto
1 reference
Hironori Koga
1 reference
Takato Ueno
1 reference
Hirohisa Yano
1 reference
Michio Sata
1 reference
18 May 2012
1 reference
1 reference
18
1 reference
14
1 reference
3924-3933
1 reference
Identifiers
1 reference
1 reference